Healthcare Sector Intelligence

Healthcare sector underperformed with XLV declining 1.8% over the past month, reflecting broader headwinds across traditional pharma and medical device names. VNDA emerged as a standout performer with a 27.1% surge, likely driven by positive clinical trial developments or regulatory progress that significantly outpaced sector fundamentals. The divergence between individual biotech momentum and sector-wide weakness suggests investors are rotating toward high-conviction plays with clear catalysts while avoiding broader healthcare exposure amid pricing pressures and regulatory scrutiny.